BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  GLP-1

  Novo Nordisk’s Ozempic Could Help Curb Cigarette Use in Diabetics: Study

  Adding to growing evidence of its benefits beyond glucose control and weight loss, Novo Nordisk’s Ozempic could also potentially help diabetics quit smoking, according to new research.

  July 30, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Inflammatory bowel disease

  Ventyx Ends Development of TYK2 Inhibitor After Phase II Flop in Crohn’s Disease

  Back-to-back failures in psoriasis and Crohn’s disease have forced Ventyx Biosciences to abandon the development of its investigational oral TYK2 inhibitor VTX958.

  July 30, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Novo’s Older GLP-1 Drug Slows Cognitive Decline in Phase IIb Alzheimer’s Trial

  Cognitive function in the liraglutide cohort declined 18% slower than in the placebo arm over one year of treatment, researchers announced Tuesday at the Alzheimer’s Association International Conference.

  July 30, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Cancer

  AstraZeneca’s Calquence Aces Phase III CLL Trial, Eyes Fixed-Duration Approval

  AstraZeneca is seeking a fixed-duration approval for Calquence, which will allow patients with chronic lymphocytic leukemia to take breaks from the therapy and prevent excessive toxicities and drug resistance.

  July 30, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Pfizer, Merck Beat Wall Street Expectations Amid Strong Biopharma Q2 Earnings Season

  Second-quarter revenues were better than analysts expected as Merck reported 16% growth for its blockbuster cancer treatment Keytruda, while Pfizer benefited from its ongoing cost-cutting efforts and sales of its COVID-19 antiviral Paxlovid.

  July 30, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Cancer

  BioNTech, Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma

  BioNTech and Regeneron will face off against Merck and Moderna, which are advancing their investigational cancer vaccine mRNA-4157/V940 in combination with Keytruda, in advanced melanoma.

  July 30, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  GSK, Flagship Commit $150M Upfront for Initial Development of Respiratory, Immunology Programs

  Flagship Pioneering and its portfolio companies are in line to receive up to $720 million in milestones for each of the 10 programs that GSK could option, according to Monday’s announcement.

  July 30, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• Press Releases

  Verona Pharma to Present at 44th Annual Canaccord Growth Conference

  July 30, 2024

   · 

  1 min read
• Press Releases

  Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire

  July 30, 2024

   · 

  5 min read
• Press Releases

  Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

  July 30, 2024

   · 

  8 min read